Open AccessA circRNA signature predicts postoperative recurrence in stage II/III colon cancer
Author(s) -
Ju HuaiQiang,
Zhao Qi,
Wang Feng,
Lan Ping,
Wang Zixian,
Zuo ZhiXiang,
Wu QiNian,
Fan XinJuan,
Mo HaiYu,
Chen Li,
Li Ting,
Ren Chao,
Wan XiangBo,
Chen Gong,
Li YuHong,
Jia WeiHua,
Xu RuiHua
Publication year - 2019
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.201810168
Subject(s) - stage (stratigraphy) , colorectal cancer , cancer , medicine , signature (topology) , oncology , cancer research , biology , mathematics , paleontology , geometry
Accurate risk stratification for patients with stage II / III colon cancer is pivotal for postoperative treatment decisions. Here, we aimed to identify and validate a circ RNA ‐based signature that could improve postoperative prognostic stratification for these patients. In current retrospective analysis, we included 667 patients with R0 resected stage II / III colon cancer. Using RNA ‐seq analysis of 20 paired frozen tissues collected postoperation, we profiled differential circ RNA expression between patients with and without recurrence, followed by quantitative validation. With clinical information, we generated a four‐circ RNA ‐based cirScore to classify patients into high‐risk and low‐risk groups in the training cohort. The patients with high cirScores in the training cohort had a shorter disease‐free survival ( DFS ) and overall survival ( OS ) than patients with low cirScores. The prognostic capacity of the classifier was validated in the internal and external cohorts. Loss‐of‐function assays indicated that the selected circ RNA s played functional roles in colon cancer progression. Overall, our four‐circ RNA ‐based classifier is a reliable prognostic tool for postoperative disease recurrence in patients with stage II / III colon cancer.